Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival
about
Micrornas in prostate cancer: an overview.First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel.Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.Current treatment strategies for advanced prostate cancer.Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer.
P2860
Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Very Early PSA Response to Abi ...... or Predicting Overall Survival
@en
type
label
Very Early PSA Response to Abi ...... or Predicting Overall Survival
@en
prefLabel
Very Early PSA Response to Abi ...... or Predicting Overall Survival
@en
P2093
P2860
P50
P356
P1476
Very Early PSA Response to Abi ...... or Predicting Overall Survival
@en
P2093
Carmine D'Aniello
Cinzia Ortega
Fiorella Ruatta
Francesca Maines
Marilena Di Napoli
Massimiliano Berretta
Orazio Caffo
Sabrina C Cecere
Salvatore Pisconti
P2860
P356
10.3389/FPHAR.2016.00123
P50
P577
2016-05-18T00:00:00Z